$FBIO Q2 '26 Earnings Results & Recap Fortress Biotech reported Q1 2026 consolidated net income of $108.4 million, or $2.82 per diluted share, driven by a $205 million priority review voucher sale, compared to a prior year loss.
$FBIO Q2 '26 Earnings Results & Recap Fortress Biotech reported Q1 2026 consolidated net income of $108.4 million, or $2.82 per diluted share, driven by a $205 million priority review voucher sale, compared to a prior year loss.